FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890816104> ?p ?o ?g. }

• W2890816104 endingPage "149" @default.
• W2890816104 startingPage "149" @default.
• W2890816104 abstract "In the present study, the screening of Mirabegron (MBR) co-amorphous was performed to produce water-soluble and thermodynamically stable MBR co-amorphous with the purpose of overcoming the water solubility problem of MBR. MBR is Biopharmaceutics Classification System (BCS) class II drug used for the treatment of an overreactive bladder. The co-amorphous screening was carried out by means of the vacuum evaporation crystallization technique in methanol solvent using three water-soluble carboxylic acids, characterized by a pKa difference greater than 3 with MBR such as fumaric acid (FA), l-pyroglutamic acid (PG), and citric acid (CA). Powder X-ray diffraction (PXRD) results suggested that all solid materials produced at MBR-FA (1 equivalent (eq.)/1 equivalent (eq.)), MBR-PG (1 eq./1 eq.), and MBR-CA (1 eq./1 eq.) conditions were amorphous state solid materials. Furthermore, by means of solution-state nuclear magnetic resonance (NMR) (¹H, 13C, and 2D) and attenuated total reflection Fourier transform infrared (ATR-FTIR) spectroscopy, we could assess that MBR and carboxylic acid molecules were linked via ionic interactions to produce MBR co-amorphous. Besides, solid-state cross polarization (CP)/magic angle spinning (MAS) 13C-NMR analysis was conducted for additional assessment of MBR co-amorphous. Afterwards, dissolution tests of MBR co-amorphouses, MBR crystalline solid, and MBR amorphous were carried out for 12 h to evaluate and to compare their solubilities, dissolution rates, and phase transformation phenomenon. Here, the results suggested that MBR co-amorphouses displayed more than 57-fold higher aqueous solubility compared to MBR crystalline solid, and PXRD monitoring result suggested that MBR co-amorphouses were able to maintain their amorphous state for more than 12 h. The same results revealed that MBR amorphous exhibited increased solubility of approximatively 6.7-fold higher compared to MBR crystalline solid. However, the PXRD monitoring result suggested that MBR amorphous undergo rapid phase transformation to crystalline form in just 35 min and that within an hour all MBR amorphous are completely converted to crystalline solid. Accordingly, the increase in MBR co-amorphous' solubility was attributed to the presence of ionic interactions in MBR co-amorphous molecules. Moreover, from the differential scanning calorimetry (DSC) monitoring results, we predicted that the high glass transition temperature (Tg) of MBR co-amorphous compared to MBR amorphous was the main factor influencing the phase stability of MBR co-amorphous." @default.
• W2890816104 created "2018-09-27" @default.
• W2890816104 creator A5013985554 @default.
• W2890816104 creator A5021234575 @default.
• W2890816104 creator A5039986835 @default.
• W2890816104 creator A5041887244 @default.
• W2890816104 creator A5046267984 @default.
• W2890816104 creator A5052069466 @default.
• W2890816104 creator A5068800864 @default.
• W2890816104 creator A5072478737 @default.
• W2890816104 creator A5075143500 @default.
• W2890816104 creator A5077511513 @default.
• W2890816104 creator A5088475832 @default.
• W2890816104 date "2018-09-05" @default.
• W2890816104 modified "2023-10-18" @default.
• W2890816104 title "Co-Amorphous Screening for the Solubility Enhancement of Poorly Water-Soluble Mirabegron and Investigation of Their Intermolecular Interactions and Dissolution Behaviors" @default.
• W2890816104 cites W1210478381 @default.
• W2890816104 cites W1541736117 @default.
• W2890816104 cites W1967935934 @default.
• W2890816104 cites W1977645028 @default.
• W2890816104 cites W1981814236 @default.
• W2890816104 cites W1987980346 @default.
• W2890816104 cites W1989433514 @default.
• W2890816104 cites W1990782965 @default.
• W2890816104 cites W1992478909 @default.
• W2890816104 cites W2040432233 @default.
• W2890816104 cites W2042502385 @default.
• W2890816104 cites W2044146593 @default.
• W2890816104 cites W2044594845 @default.
• W2890816104 cites W2044829159 @default.
• W2890816104 cites W2072253461 @default.
• W2890816104 cites W2075179133 @default.
• W2890816104 cites W2078814811 @default.
• W2890816104 cites W2096105051 @default.
• W2890816104 cites W2154804998 @default.
• W2890816104 cites W2259551515 @default.
• W2890816104 cites W2275521990 @default.
• W2890816104 cites W2419595988 @default.
• W2890816104 cites W2761331723 @default.
• W2890816104 cites W2794381070 @default.
• W2890816104 doi "https://doi.org/10.3390/pharmaceutics10030149" @default.
• W2890816104 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6161252" @default.
• W2890816104 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30189645" @default.
• W2890816104 hasPublicationYear "2018" @default.
• W2890816104 type Work @default.
• W2890816104 sameAs 2890816104 @default.
• W2890816104 citedByCount "20" @default.
• W2890816104 countsByYear W28908161042018 @default.
• W2890816104 countsByYear W28908161042019 @default.
• W2890816104 countsByYear W28908161042020 @default.
• W2890816104 countsByYear W28908161042021 @default.
• W2890816104 countsByYear W28908161042022 @default.
• W2890816104 countsByYear W28908161042023 @default.
• W2890816104 crossrefType "journal-article" @default.
• W2890816104 hasAuthorship W2890816104A5013985554 @default.
• W2890816104 hasAuthorship W2890816104A5021234575 @default.
• W2890816104 hasAuthorship W2890816104A5039986835 @default.
• W2890816104 hasAuthorship W2890816104A5041887244 @default.
• W2890816104 hasAuthorship W2890816104A5046267984 @default.
• W2890816104 hasAuthorship W2890816104A5052069466 @default.
• W2890816104 hasAuthorship W2890816104A5068800864 @default.
• W2890816104 hasAuthorship W2890816104A5072478737 @default.
• W2890816104 hasAuthorship W2890816104A5075143500 @default.
• W2890816104 hasAuthorship W2890816104A5077511513 @default.
• W2890816104 hasAuthorship W2890816104A5088475832 @default.
• W2890816104 hasBestOaLocation W28908161041 @default.
• W2890816104 hasConcept C127413603 @default.
• W2890816104 hasConcept C13965031 @default.
• W2890816104 hasConcept C155574463 @default.
• W2890816104 hasConcept C160892712 @default.
• W2890816104 hasConcept C178790620 @default.
• W2890816104 hasConcept C185592680 @default.
• W2890816104 hasConcept C203036418 @default.
• W2890816104 hasConcept C42360764 @default.
• W2890816104 hasConcept C56052488 @default.
• W2890816104 hasConcept C66974803 @default.
• W2890816104 hasConcept C84935128 @default.
• W2890816104 hasConcept C88380143 @default.
• W2890816104 hasConceptScore W2890816104C127413603 @default.
• W2890816104 hasConceptScore W2890816104C13965031 @default.
• W2890816104 hasConceptScore W2890816104C155574463 @default.
• W2890816104 hasConceptScore W2890816104C160892712 @default.
• W2890816104 hasConceptScore W2890816104C178790620 @default.
• W2890816104 hasConceptScore W2890816104C185592680 @default.
• W2890816104 hasConceptScore W2890816104C203036418 @default.
• W2890816104 hasConceptScore W2890816104C42360764 @default.
• W2890816104 hasConceptScore W2890816104C56052488 @default.
• W2890816104 hasConceptScore W2890816104C66974803 @default.
• W2890816104 hasConceptScore W2890816104C84935128 @default.
• W2890816104 hasConceptScore W2890816104C88380143 @default.
• W2890816104 hasIssue "3" @default.
• W2890816104 hasLocation W28908161041 @default.
• W2890816104 hasLocation W28908161042 @default.
• W2890816104 hasLocation W28908161043 @default.
• W2890816104 hasLocation W28908161044 @default.
• W2890816104 hasLocation W28908161045 @default.
• W2890816104 hasOpenAccess W2890816104 @default.
• W2890816104 hasPrimaryLocation W28908161041 @default.

• next